Health Care Related Organization – Page 4

Kymera Snags Gilead as New Partner; Sanofi Opts for Next-Gen IRAK4 Degrader

1 month ago talkbio0Tagged biotech collaborations, CDK2 protein, human, Degrader, Gilead Sciences, IRAK4 gene, Kymera, Malignant neoplasm of breast, Molecular Glue Degrader, oncology partnership, sanofi, Solid Neoplasm

Kymera Therapeutics; Gilead Sciences; Sanofi; molecular glue degrader; CDK2; solid tumors; breast cancer; oncology partnership; IRAK4 degrader; biotech collaborations

Kymera Faces Sanofi Setback but Secures $750M Gilead Oncology Deal

1 month ago talkbio0Tagged CDK2 protein, human, Gilead, Kymera, Molecular Glue Degrader, Neoplasms, protein degrader, sanofi

Kymera; Sanofi; Gilead; molecular glue degrader; CDK2; oncology; deal; protein degrader

BrightGene’s BGM0504 Outperforms Novo Nordisk’s Semaglutide in Diabetes Trial, Eyes Showdown with Zepbound

1 month ago talkbio0Tagged BGM0504, BrightGene, Clinical Trials, Diabetes, eli lilly, GLP-1/GIP receptor agonist, Glycosylated hemoglobin A, Nordisk, Obesity, semaglutide, Weight maintenance regimen, Zepbound

BrightGene; diabetes; GLP-1/GIP receptor agonist; BGM0504; semaglutide; Novo Nordisk; Eli Lilly; Zepbound; clinical trial; HbA1c reduction; obesity; weight management

Sen. Bill Cassidy Calls for Deferral of CDC Vaccine Meeting After RFK Jr. Panel Shakeup

1 month ago talkbio0Tagged ACIP, Advisory Committees, Bill Cassidy, Centers for Disease Control and Prevention (U.S.), Confirmation, Deferred, HELP Committee, Policy, RFK Jr., Senate, Vaccines

Bill Cassidy; RFK Jr.; CDC; vaccine advisory committee; ACIP; confirmation; deferral; Senate HELP Committee; vaccine policy

Sanofi Licenses Formation Bio’s JAK/SYK Inhibitor Gusacitinib in $630M+ AI-Driven Deal

1 month ago talkbio0Tagged AI drug development, Anabolism, Bio, chronic hand eczema, gusacitinib, Indication of (contextual qualifier), JAK/SYK inhibitor, Libertas Bio, licensing agreement, sanofi

Sanofi; Formation Bio; gusacitinib; JAK/SYK inhibitor; AI drug development; Libertas Bio; deal; chronic hand eczema; new indication; licensing agreement

Diabetes and Obesity Drug Boom to Propel Lilly and Novo Nordisk to Pharma Sales Leadership by 2030: Evaluate

1 month ago talkbio0Tagged CagriSema, Diabetes, eli lilly, Evaluate report, Mounjaro, Nordisk, Obesity, Ozempic, Pharmaceutical Sales, semaglutide, tirzepatide, top-selling drugs, Wegovy, Zepbound

diabetes; obesity; pharmaceutical sales; Eli Lilly; Novo Nordisk; Evaluate report; top-selling drugs; tirzepatide; semaglutide; Mounjaro; Zepbound; Ozempic; Wegovy; CagriSema; 2030 forecast